These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 17397665)
1. Development of a competitive immunoassay for efavirenz: hapten design and validation studies. Roucairol C; Azoulay S; Nevers MC; Créminon C; Grassi J; Burger A; Duval D Anal Chim Acta; 2007 Apr; 589(1):142-9. PubMed ID: 17397665 [TBL] [Abstract][Full Text] [Related]
2. An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients. Azoulay S; Nevers MC; Créminon C; Heripret L; Garraffo R; Durant J; Dellamonica P; Grassi J; Guedj R; Duval D J Immunol Methods; 2004 Dec; 295(1-2):37-48. PubMed ID: 15627609 [TBL] [Abstract][Full Text] [Related]
3. Determination of salivary efavirenz by liquid chromatography coupled with tandem mass spectrometry. Theron A; Cromarty D; Rheeders M; Viljoen M J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Oct; 878(28):2886-90. PubMed ID: 20869336 [TBL] [Abstract][Full Text] [Related]
4. Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells. Roucairol C; Azoulay S; Nevers MC; Créminon C; Lavrut T; Garraffo R; Grassi J; Burger A; Duval D Antimicrob Agents Chemother; 2007 Feb; 51(2):405-11. PubMed ID: 17116661 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry. Nirogi R; Bhyrapuneni G; Kandikere V; Mudigonda K; Komarneni P; Aleti R; Mukkanti K Biomed Chromatogr; 2009 Apr; 23(4):371-81. PubMed ID: 18937306 [TBL] [Abstract][Full Text] [Related]
6. Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. Curley P; Siccardi M; Moss DM; Owen A Bioanalysis; 2016 Oct; 8(20):2125-34. PubMed ID: 27611731 [TBL] [Abstract][Full Text] [Related]
7. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. Quaranta S; Woloch C; Paccou A; Giocanti M; Solas C; Lacarelle B Ther Drug Monit; 2009 Dec; 31(6):695-702. PubMed ID: 19865000 [TBL] [Abstract][Full Text] [Related]
8. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ter Heine R; Alderden-Los CG; Rosing H; Hillebrand MJ; van Gorp EC; Huitema AD; Beijnen JH Rapid Commun Mass Spectrom; 2007; 21(15):2505-14. PubMed ID: 17610214 [TBL] [Abstract][Full Text] [Related]
9. Rapid method for the quantitative determination of efavirenz in human plasma. Mogatle S; Kanfer I J Pharm Biomed Anal; 2009 Jul; 49(5):1308-12. PubMed ID: 19375262 [TBL] [Abstract][Full Text] [Related]
10. Mass spectrometric quantification of AcSDKP-NH2 in human plasma and urine and comparison with an immunoassay. Mesmin C; Cholet S; Blanchard A; Chambon Y; Azizi M; Ezan E Rapid Commun Mass Spectrom; 2012 Jan; 26(2):163-72. PubMed ID: 22173804 [TBL] [Abstract][Full Text] [Related]
11. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680 [TBL] [Abstract][Full Text] [Related]
12. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160 [TBL] [Abstract][Full Text] [Related]
13. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. D'Avolio A; Baietto L; Siccardi M; Sciandra M; Simiele M; Oddone V; Bonora S; Di Perri G Ther Drug Monit; 2008 Dec; 30(6):662-9. PubMed ID: 18824956 [TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. Rezk NL; Tidwell RR; Kashuba AD J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(2):241-7. PubMed ID: 15135096 [TBL] [Abstract][Full Text] [Related]
15. Development of antibodies for the detection of N-acetyl-glufosinate. Weller MG; Diemer M; Wersching C; Niessner R; Sochor H J Agric Food Chem; 2003 Nov; 51(23):6668-75. PubMed ID: 14582958 [TBL] [Abstract][Full Text] [Related]
16. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Koal T; Burhenne H; Römling R; Svoboda M; Resch K; Kaever V Rapid Commun Mass Spectrom; 2005; 19(21):2995-3001. PubMed ID: 16193530 [TBL] [Abstract][Full Text] [Related]
17. Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz. Mutlib AE; Chen H; Nemeth G; Gan LS; Christ DD Drug Metab Dispos; 1999 Sep; 27(9):1045-56. PubMed ID: 10460805 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry. Rouzes A; Berthoin K; Xuereb F; Djabarouti S; Pellegrin I; Pellegrin JL; Coupet AC; Augagneur S; Budzinski H; Saux MC; Breilh D J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):209-16. PubMed ID: 15556535 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy. Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157 [TBL] [Abstract][Full Text] [Related]
20. Successful efavirenz dose reduction guided by therapeutic drug monitoring. Fayet Mello A; Buclin T; Decosterd LA; Delhumeau C; di Iulio J; Fleurent A; Schneider MP; Cavassini M; Telenti A; Hirschel B; Calmy A Antivir Ther; 2011; 16(2):189-97. PubMed ID: 21447868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]